485 related articles for article (PubMed ID: 30805949)
1. NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.
Harrison SA; Rossi SJ; Paredes AH; Trotter JF; Bashir MR; Guy CD; Banerjee R; Jaros MJ; Owers S; Baxter BA; Ling L; DePaoli AM
Hepatology; 2020 Apr; 71(4):1198-1212. PubMed ID: 30805949
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
Rinella ME; Trotter JF; Abdelmalek MF; Paredes AH; Connelly MA; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Harrison SA
J Hepatol; 2019 Apr; 70(4):735-744. PubMed ID: 30529590
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
[TBL] [Abstract][Full Text] [Related]
4. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Rinella ME; Abdelmalek MF; Trotter JF; Paredes AH; Arnold HL; Kugelmas M; Bashir MR; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Loomba R
Lancet; 2018 Mar; 391(10126):1174-1185. PubMed ID: 29519502
[TBL] [Abstract][Full Text] [Related]
5. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
6. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study.
Loomba R; Sanyal AJ; Nakajima A; Neuschwander-Tetri BA; Goodman ZD; Harrison SA; Lawitz EJ; Gunn N; Imajo K; Ravendhran N; Akahane T; Boone B; Yamaguchi M; Chatterjee A; Tirucherai GS; Shevell DE; Du S; Charles ED; Abdelmalek MF
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):102-112.e9. PubMed ID: 37088457
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K
JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237
[TBL] [Abstract][Full Text] [Related]
8. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
[TBL] [Abstract][Full Text] [Related]
9. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
[TBL] [Abstract][Full Text] [Related]
10. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
Harrison SA; Abdelmalek MF; Caldwell S; Shiffman ML; Diehl AM; Ghalib R; Lawitz EJ; Rockey DC; Schall RA; Jia C; McColgan BJ; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Ratziu V; Muir AJ; Afdhal NH; Goodman Z; Bosch J; Sanyal AJ;
Gastroenterology; 2018 Oct; 155(4):1140-1153. PubMed ID: 29990488
[TBL] [Abstract][Full Text] [Related]
11. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
12. Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.
Abdelmalek MF; Sanyal AJ; Nakajima A; Neuschwander-Tetri BA; Goodman ZD; Lawitz EJ; Harrison SA; Jacobson IM; Imajo K; Gunn N; Halegoua-DeMarzio D; Akahane T; Boone B; Yamaguchi M; Chatterjee A; Tirucherai GS; Shevell DE; Du S; Charles ED; Loomba R
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):113-123.e9. PubMed ID: 37088458
[TBL] [Abstract][Full Text] [Related]
13. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Newsome PN; Buchholtz K; Cusi K; Linder M; Okanoue T; Ratziu V; Sanyal AJ; Sejling AS; Harrison SA;
N Engl J Med; 2021 Mar; 384(12):1113-1124. PubMed ID: 33185364
[TBL] [Abstract][Full Text] [Related]
14. Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.
Anstee QM; Neuschwander-Tetri BA; Wong VW; Abdelmalek MF; Younossi ZM; Yuan J; Pecoraro ML; Seyedkazemi S; Fischer L; Bedossa P; Goodman Z; Alkhouri N; Tacke F; Sanyal A
Contemp Clin Trials; 2020 Feb; 89():105922. PubMed ID: 31881392
[TBL] [Abstract][Full Text] [Related]
15. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Abdelmalek MF; Charles ED; Sanyal AJ; Harrison SA; Neuschwander-Tetri BA; Goodman Z; Ehman RA; Karsdal M; Nakajima A; Du S; Tirucherai GS; Klinger GH; Mora J; Yamaguchi M; Shevell DE; Loomba R
Contemp Clin Trials; 2021 May; 104():106335. PubMed ID: 33657443
[TBL] [Abstract][Full Text] [Related]
16. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
[TBL] [Abstract][Full Text] [Related]
17. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Loomba R; Noureddin M; Kowdley KV; Kohli A; Sheikh A; Neff G; Bhandari BR; Gunn N; Caldwell SH; Goodman Z; Wapinski I; Resnick M; Beck AH; Ding D; Jia C; Chuang JC; Huss RS; Chung C; Subramanian GM; Myers RP; Patel K; Borg BB; Ghalib R; Kabler H; Poulos J; Younes Z; Elkhashab M; Hassanein T; Iyer R; Ruane P; Shiffman ML; Strasser S; Wong VW; Alkhouri N;
Hepatology; 2021 Feb; 73(2):625-643. PubMed ID: 33169409
[TBL] [Abstract][Full Text] [Related]
18. Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.
Sanyal AJ; Ling L; Beuers U; DePaoli AM; Lieu HD; Harrison SA; Hirschfield GM
JHEP Rep; 2021 Jun; 3(3):100255. PubMed ID: 33898959
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
[TBL] [Abstract][Full Text] [Related]
20. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Sanyal A; Charles ED; Neuschwander-Tetri BA; Loomba R; Harrison SA; Abdelmalek MF; Lawitz EJ; Halegoua-DeMarzio D; Kundu S; Noviello S; Luo Y; Christian R
Lancet; 2019 Dec; 392(10165):2705-2717. PubMed ID: 30554783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]